-
Press Room
-
Press Releases
-
May 11, 2021
9:15 PM
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
-
May 06, 2021
1:30 PM
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
-
Mar 31, 2021
1:45 PM
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
-
Mar 30, 2021
1:45 PM
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
-
Mar 29, 2021
9:15 PM
VolitionRx Limited Appoints Two New Directors
-
Mar 22, 2021
8:15 PM
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
-
Mar 17, 2021
12:15 PM
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
-
Mar 16, 2021
12:45 PM
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
-
Mar 08, 2021
9:30 PM
VolitionRx Limited to Present at Conferences in March 2021
-
Feb 12, 2021
2:30 PM
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
-
Feb 10, 2021
2:30 PM
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
-
Feb 09, 2021
9:15 PM
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
-
Feb 02, 2021
1:00 PM
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
-
Jan 28, 2021
11:30 AM
National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
-
Jan 25, 2021
2:00 PM
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
-
Jan 06, 2021
1:30 PM
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding